Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes

Investigators conducted a Phase I–II study of zimislecel in persons with type 1 diabetes. In part A, participants received a half dose of zimislecel as a single infusion into the portal vein, with an option for a second half dose within two years. In parts B and C, participants received a full dose of zimislecel as a single infusion.